In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Rudolf De Boer
Speaker
Rudolf De Boer
Rudolf De Boer Rudolf De Boer

University Medical Center Groningen, Groningen (Netherlands (The))

Specialities : Chronic Heart Failure , Basic Science

De Boer is a translational cardiologist; overall goal is to gain further insight in the processes of myocardial remodeling and prevent cardiovascular disease. He is experienced in conducting clinical and preclinical projects. His main research interests are myocardial remodeling, fibrosis, diabetes, cardio-oncology and genetics of heart failure. He is director of the experimental cardiology section of the UMC Groningen, the Netherlands. De Boer is active in ESC: he was an HFA Board member (2014-2020), member of the ESC Advocacy, Education and eHealth committees, and is currently liaison officer of the ESC Council on Cardio-Oncology.

47 presentations from this speaker

Assessing the full impact of DAPA-HF - Panel discussion and Q&A.

Event : ESC Congress 2020

  • Session : Learning from DAPA-HF one year on
  • Speaker : JJV McMurray (Glasgow,GB), S Solomon (Boston,US), C Ljungman (V Frolunda,SE), S Verma (Toronto,CA), R De Boer (Groningen,NL)
  • Organised by ChangeIME, supported by AstraZeneca in the form of an educational grant

Hot Line EMPEROR-Reduced.

Event : ESC Congress 2020

  • Session : Hot Line EMPEROR-Reduced
  • Speaker : B Casadei (Oxford,GB), R De Boer (Groningen,NL), M Packer (Dallas,US), M Metra (Brescia,IT)

Hot Line PARALLAX.

Event : ESC Congress 2020

  • Session : Hot Line PARALLAX
  • Speaker : BJ Mulder (Amsterdam,NL), F Ruschitzka (Zurich,CH), B Pieske (Berlin,DE), R De Boer (Groningen,NL)

How to implement SGLT2 inhibitor trial results into clinical practice?

Event : ESC Congress 2020

  • Session : How To Implement Heart Failure Clinical Trial Results into Practice?
  • Speaker : R De Boer (Groningen,NL)

Learning from DAPA-HF one year on: Expert on the spot - Sponsored by AstraZeneca.

Event : ESC Congress 2020

  • Session : Learning from DAPA-HF one year on: Expert on the spot
  • Speaker : JJV McMurray (Glasgow,GB), R De Boer (Groningen,NL)
  • Organised by ChangeIME, supported by AstraZeneca in the form of an educational grant

Next generation RNA therapeutics. Background and clinical development in cardiovascular disease.

Event : Webinar 2020

  • Session : HFA Webinars 2020
  • Speaker : G Condorelli (Rozzano,IT), R De Boer (Groningen,NL), T Thum (Hannover,DE)

Practicing new learnings safely in HFrEF.

Event : ESC Congress 2020

  • Session : Learning from DAPA-HF one year on
  • Speaker : R De Boer (Groningen,NL)
  • Organised by ChangeIME, supported by AstraZeneca in the form of an educational grant

Prevention of heart failure with SGLT-2 inhibitors: from mechanisms to clinical benefit.

Event : HFA Discoveries 2020

  • Session : SGLT-2 inhibitors in heart failure: beyond glycaemic control
  • Speaker : R De Boer (Groningen,NL)

SGLT-2 inhibitors in heart failure: beyond glycaemic control.

Event : HFA Discoveries 2020

  • Session : SGLT-2 inhibitors in heart failure: beyond glycaemic control
  • Speaker : R De Boer (Groningen,NL), P Seferovic (Belgrade,RS)

SGLT2 inhibitors should be given to all patients with heart failure - CON.

Event : ESC Congress 2020

  • Session : Controversies in Heart Failure: SGLT2 Inhibitors Should Be Given to All Patients
  • Speaker : R De Boer (Groningen,NL)

Case 2: should Infection in acute heart failure get special attention?

Event : ESC Congress 2019

  • Session : Meet the Experts - Triggers of AHF
  • Speaker : R De Boer (Groningen,NL)

Heart failure promotes cancer or vice versa?

Event : Heart Failure 2019

  • Session : Cancer and heart failure: enemies in treatment?
  • Speaker : R De Boer (Groningen,NL)

HFpEF from mechanisms to diagnosis.

Event : Webinar 2019

  • Session : HFA Webinars 2019
  • Speaker : A Coats (Warwickshire,GB), R De Boer (Groningen,NL), B Pieske (Berlin,DE)

Introduction - Reshaping the future of heart failure management - Translating innovations to practice in HFpEF.

Event : Heart Failure 2019

  • Session : Reshaping the future of heart failure management - Translating innovations to practice in HFpEF
  • Speaker : R De Boer (Groningen,NL), D van Veldhuisen (Groningen,NL)
  • Organised by PACE-CME - Physicians' Academy for Cardiovascular Education, supported with educational grants provided by Novartis, Novo Nordisk and Pfizer

Medical Interventions.

Event : Heart Failure 2019

  • Session : Clinical approach to cardio-oncological patient
  • Speaker : R De Boer (Groningen,NL)

Panel discussion - Reshaping the future of heart failure management - Translating innovations to practice in HFpEF.

Event : Heart Failure 2019

  • Session : Reshaping the future of heart failure management - Translating innovations to practice in HFpEF
  • Speaker : R De Boer (Groningen,NL), D van Veldhuisen (Groningen,NL)
  • Organised by PACE-CME - Physicians' Academy for Cardiovascular Education, supported with educational grants provided by Novartis, Novo Nordisk and Pfizer

Targeting fibrosis: pirfenidone and beyond.

Event : Heart Failure 2019

  • Session : Upcoming and novel drugs in heart failure
  • Speaker : R De Boer (Groningen,NL)

The failing heart stimulates tumor growth by circulating factors

Event : ESC Congress 2019

  • Session : Cardio-Oncology: Novel mechanisms and clinical implications
  • Speaker : R De Boer (Groningen,NL)

A patient with HFpEF and diabetes - What do the guidelines say?

Event : Heart Failure 2018

  • Session : Guidelines in daily practice V - HFpEF
  • Speaker : R De Boer (Groningen,NL)

Are SGTL2 inhibitors good for the heart?

Event : Heart Failure 2018

  • Session : Lessons learnt from recent clinical trial outcomes
  • Speaker : R De Boer (Groningen,NL)

Biomarkers and imaging

Event : Heart Failure 2018

  • Session : Heart Failure 2018 Highlights
  • Speaker : R De Boer (Groningen,NL)

Diabetes & obesity in HFpEF: new targets in heart failure management.

Event : Heart Failure 2018

  • Session : Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction
  • Speaker : R De Boer (Groningen,NL)
  • Organised by PACE and UMCG, supported with educational grants by Novartis and Novo Nordisk

Does heart failure predispose to cancer?

Event : Heart Failure 2018

  • Session : Tips and tricks in cardio-oncology
  • Speaker : R De Boer (Groningen,NL)

Is cancer more frequent in heart failure?

Event : Heart Failure 2018

  • Session : Where does cardiology meet oncology?
  • Speaker : R De Boer (Groningen,NL)

Novel biomarkers

Event : Heart Failure 2018

  • Session : Biomarkers - Future directions
  • Speaker : R De Boer (Groningen,NL)

Panel discussion.

Event : Heart Failure 2018

  • Session : Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction
  • Speaker : D van Veldhuisen (Groningen,NL), D Kotecha (Birmingham,GB), A Voors (Groningen,NL), R De Boer (Groningen,NL)
  • Organised by PACE and UMCG, supported with educational grants by Novartis and Novo Nordisk

SGLT2 inhibition and heart failure: a different way of thinking?

Event : ESC Congress 2018

  • Session : SGLT2 inhibition and heart failure: a different way of thinking? (EBAC Accredited)
  • Speaker : A Voors (Groningen,NL), M Cavender (Boston,US), R De Boer (Groningen,NL), T McDonagh (London,GB)
  • Sponsored by AstraZeneca

Biomarkers changed my daily practice!

Event : Heart Failure 2017

  • Session : Biomarkers in chronic heart failure
  • Speaker : R De Boer (Groningen,NL)

Rationale for a new furosemide product 50 years after its first introduction.

Event : Heart Failure 2017

  • Session : Furosemide 2.0 - Subcutaneous administration of a novel formulation
  • Speaker : R De Boer (Groningen,NL)
  • Sponsored by scPharmaceuticals, Inc.

Rationale for a new furosemide product 50 years after its first introduction.

Event : Heart Failure 2017

  • Session : Furosemide 2.0 - Subcutaneous administration of a novel formulation
  • Speaker : R De Boer (Groningen,NL)
  • Sponsored by scPharmaceuticals

Renal function parameters in acute heart failure

Event : ESC Congress 2017

  • Session : How to interpret laboratory tests in acute heart failure
  • Speaker : R De Boer (Groningen,NL)

State of the Art: HFmrEF - The new middle child

Event : ESC Congress 2017

  • Session : Heart failure with mid-range and preserved ejection fraction
  • Speaker : R De Boer (Groningen,NL)

Targeting fibrosis.

Event : Heart Failure 2017

  • Session : Highlights of translational medicine
  • Speaker : R De Boer (Groningen,NL)

Young investigator award: basic science.

Event : Heart Failure 2017

  • Session : Award Ceremony
  • Speaker : R De Boer (Groningen,NL)

Biomarkers and diagnostic devices in patients with comorbidities

Event : ESC Congress 2016

  • Session : What a cardiologist should know about heart failure with comorbidities
  • Speaker : R De Boer (Groningen,NL)
  • Organised by Heart Failure Assciation of the ESC

Diuretics.

Event : Heart Failure 2016

  • Session : Individualising therapy in heart failure
  • Speaker : R De Boer (Groningen,NL)

Future direction for research in biomarkers in ventricular dysfunction.

Event : ESC Congress 2016

  • Session : Biomarkers in heart failure and ventricular dysfunction: update 2016
  • Speaker : R De Boer (Groningen,NL)

HfpEF 2020: opportunities to intervene

Event : Heart Failure 2016

  • Session : Directions in HFpEF research
  • Speaker : R De Boer (Groningen,NL)

Pathophysiology and the clinical consequences of myocardial fibrosis.

Event : ESC Congress 2016

  • Session : Cardiac fibrosis quo vadis?
  • Speaker : R De Boer (Groningen,NL)
  • Organised by Council on Basic Cardiovascular Science (CBCS)

Pharmacokinetics of furosemide following subcutaneous administration of a novel injectable formulation.

Event : Heart Failure 2016

  • Session : Furosemide 2.0: furosemide for subcutaneous administration: a novel tool in the management of the pre and post acute heart failure patient
  • Speaker : R De Boer (Groningen,NL)
  • Sponsored by scPharmaceuticals

ST-2.

Event : Heart Failure 2016

  • Session : Biomarkers in heart failure: what's new?
  • Speaker : R De Boer (Groningen,NL)

Antifibrotic agents.

Event : Heart Failure 2015

  • Session : Novel drugs: how do they work?
  • Speaker : R De Boer (Groningen,NL)

Biomarkers of kidney function - Useful or not ?

Event : ESC Congress 2015

  • Session : Biomarkers for heart failure - A reality check
  • Speaker : R De Boer (Groningen,NL)

Inflammation and fibrosis.

Event : ESC Congress 2014

  • Session : Emerging biomarkers in heart failure
  • Speaker : R De Boer (Groningen,NL)

Pathophysiology.

Event : ESC Congress 2014

  • Session : Diabetes and heart failure: liaisons dangereuses
  • Speaker : R De Boer (Groningen,NL)

Glomerular filtration rate: measure or estimate?

Event : ESC Congress 2013

  • Session : The kidney in heart failure: 2013 update
  • Speaker : R De Boer (Groningen,NL)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are